---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-092037"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2026-08-06T20:18:46+00:00"
generated_at: "2026-08-06T20:20:58.464002+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics Q2 2026 net loss $3.9M; advances Phase 3 plan for DLB psychosis

## Summary
- Net loss of $3.9M ($0.04 per share) vs $6.7M loss in Q2 2025.
- R&D expenses fell to $5.1M from $11.5M; G&A $2.6M vs $2.5M.
- Cash $34.8M plus $21.6M grant funds; runway into Q4 2027.
- FDA meeting on Phase 3 trial for DLB psychosis; initiation planned for mid-2027.
- New composition of matter patent allowed for zervimesine extending protection to 2045.

## SEC filing metadata
- accession: 0001104659-26-092037
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2026-08-06T20:18:46+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465926092037/0001104659-26-092037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465926092037/tm2622462d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-092037
- JSON: https://secwatch.observer/filing/0001104659-26-092037.json
- Plain text: https://secwatch.observer/filing/0001104659-26-092037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.